Cases from the Community: Investigators Provide Their Perspectives on the Practice Implications of Emerging Clinical Research — A Special Video SupplementChoice of chemotherapeutic regimen for a patient not eligible for an anthracycline or a taxane
1:26 minutes.
TRANSCRIPTION:
DR LOVE: Another question that we got: What is the chemo regimen of choice for a patient who you don’t want to give an anthracycline or taxane to? Quote, have you used CMP with trastuzumab. DR SMITH: There is no standard of choice if you’re not using anthracyclines and taxanes. There’s no guidelines. There are no good data. But if you look at all the early work that was done on trastuzumab, both neoadjuvant studies and in metastatic disease, whatever chemotherapy was used — there were a lot of Phase II studies, nonrandomized. And they all produced high response rates. And there was almost a message that whatever chemotherapy you’re going to use with trastuzumab is going to have a positive synergistic effect. I’m not sure I would use CMF or CMFP or whatever you suggested. But I would have said vinorelbine several times. I’ve treated someone with capecitabine who didn’t want needles and so on. There were needles, of course, for the trastuzumab. And funny enough, I saw her in my clinic this morning. And that was about 6 years ago, and she’s in complete long-term remission with simple capecitabine and trastuzumab. So maybe that or maybe vinorelbine is what I’d be looking at. DR LOVE: Interesting. |